HealthQuill Pediatric Patients
Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the treatment of generalised myasthenia gravis (gMG) — a rare disease that causes muscle weakness and affects daily activities like chewing, swallowing, speaking, and breathing.
Drugs Health Pharma

US regulator approves Johnson & Johnson’s immune disorder drug

HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.

Read More
US regulator, the FDA has approved Gilead Sciences, Inc.'s supplemental new drug application for treating chronic hepatitis B virus in paediatric patients six years of age and older.
Drugs Health Pharma

FDA nod for Gilead to expand hepatitis drug to six years or older patients

HQ Team March 28, 2024: US regulator, the FDA has approved Gilead Sciences, Inc.’s supplemental new drug application for treating chronic hepatitis B.

Read More